Arg72Pro TP53 polymorphism and cancer susceptibility: A comprehensive meta-analysis of 302 case-control studies

International Journal of Cancer

Volumn 129, Issue 4, 2011, Pages 920-930

  Francisco, Guilherme ^a,b   Menezes, Paulo Rossi ^a   Eluf Neto, José ^a   Chammas, Roger ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b Instituto do Câncer do Estado de São Paulo   (Brazil)

Author keywords

Arg72Pro; cancer susceptibility; case control; heterogeneity; meta analysis; meta regression; p53

Indexed keywords

ARGININE; PROLINE; PROTEIN P53;

ARTICLE; BLADDER CANCER; BRAIN CANCER; BREAST CANCER; CANCER RISK; CANCER SUSCEPTIBILITY; CASE CONTROL STUDY; COLORECTAL CANCER; ENDOMETRIUM CANCER; ESOPHAGUS CANCER; ETHNICITY; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC MODEL; GENETIC POLYMORPHISM; GENOTYPE; HEAD AND NECK CANCER; HEMATOLOGIC MALIGNANCY; HUMAN; LIVER CELL CARCINOMA; LUNG CANCER; MELANOMA; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; SKIN CANCER; STOMACH CANCER; SYSTEMATIC REVIEW; THYROID CANCER; TP53 GENE; TUMOR SUPPRESSOR GENE; UTERINE CERVIX CANCER;

CASE-CONTROL STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; NEOPLASMS; PENETRANCE; POLYMORPHISM, GENETIC; PROGNOSIS; RISK FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 79959732231     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25710     Document Type: Article

References (50)

1. Hainaut P, Wiman KG,. 30 years and a long way into p53 research. Lancet Oncol 2009; 10: 913-9.
2. Brosh R, Rotter V,. When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer 2009; 10: 701-13.
3. Olivier M, Petitjean A, Pétré A, Mounawar M, Plymoth A, de Fromentel CC, Hainaut P,. Recent advances in p53 research: an interdisciplinary perspective. Cancer Gene Ther 2009; 16: 1-12.
4. Achatz MI, Hainaut P, Ashton-Prolla P,. Highly prevalent TP53 mutation predisposing to many cancers in the Brazilian population: a case for newborn screening? Lancet Oncol 2009; 10: 920-5.
5. Hrstka R, Coates PJ, Vojtesek B,. Polymorphisms in p53 and the p53 pathway: roles in cancer susceptibility and response to treatment. J Cell Mol Med 2009; 13: 440-53.
6. Whibley C, Pharoah PD, Hollstein M,. p53 polymorphisms: cancer implications. Nat Rev Cancer 2009; 9: 95-107.
7. Dumont P, Leu JI, Della Pietra AC, III, George DL, Murphy M,. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 2003; 33: 357-65. (Pubitemid 36278852)
8. Storey A, Thomas M, Kalita A, Harwood C, Gardiol D, Mantovani F, Breuer J, Leigh IM, Matlashewski G, Banks L,. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature 1998; 393: 229-34. (Pubitemid 28261713)
9. Buyru N, Tigli H, Dalay N,. p53 codon 72 polymorphism in breast cancer. Oncol Rep 2003; 10: 711-4.
10. Damin AP, Frazzon AP, Damin DC, Roehe A, Hermes V, Zettler C, Alexandre CO,. Evidence for an association of TP53 codon 72 polymorphism with breast cancer risk. Cancer Detect Prev 2006; 30: 523-9. (Pubitemid 44828290)
11. Gochhait S, Bukhari SI, Bairwa N, Vadhera S, Darvishi K, Raish M, Gupta P, Husain SA, Bamezai RN,. Implication of BRCA2 -26G>A 5′ untranslated region polymorphism in susceptibility to sporadic breast cancer and its modulation by p53 codon 72 Arg>Pro polymorphism. Breast Cancer Res 2007; 9: R71.
12. Kalemi TG, Lambropoulos AF, Gueorguiev M, Chrisafi S, Papazisis KT, Kotsis A,. The association of p53 mutations and p53 codon 72, Her 2 codon 655 and MTHFR C677T polymorphisms with breast cancer in Northern Greece. Cancer Lett 2005; 222: 57-65. (Pubitemid 40544847)
13. Baynes C, Healey CS, Pooley KA, Scollen S, Luben RN, Thompson DJ, Pharoah PD, Easton DF, Ponder BA, Dunning AM,. SEARCH breast cancer study. Common variants in the ATM, BRCA1, BRCA2, CHEK2 and TP53 cancer susceptibility genes are unlikely to increase breast cancer risk. Breast Cancer Res 2007; 9: R27.
14. Gaudet MM, Gammon MD, Bensen JT, Sagiv SK, Shantakumar S, Teitelbaum SL, Eng SM, Neugut AI, Santella RM,. Genetic variation of TP53, polycyclic aromatic hydrocarbon-related exposures and breast cancer risk among women on Long Island, New York. Breast Cancer Res Treat 2008; 108: 93-9. (Pubitemid 351623233)
15. Costa S, Pinto D, Pereira D, Rodrigues H, Cameselle-Teijeiro J, Medeiros R, Schmitt F,. Importance of TP53 codon 72 and intron 3 duplication 16bp polymorphisms in prediction of susceptibility on breast cancer. BMC Cancer 2008; 8: 32.
16. Huang XE, Hamajima N, Katsuda N, Matsuo K, Hirose K, Mizutani M, Iwata H, Miura S, Xiang J, Tokudome S, Tajima K,. Association of p53 codon Arg72Pro and p73 G4C14-to-A4T14 at exon 2 genetic polymorphisms with the risk of Japanese breast cancer. Breast Cancer 2003; 10: 307-11.
17. Weston A, Pan CF, Ksieski HB, Wallenstein S, Berkowitz GS, Tartter PI, Bleiweiss IJ, Brower ST, Senie RT, Wolff MS,. p53 haplotype determination in breast cancer. Cancer Epidemiol Biomarkers Prev 1997; 6: 105-12. (Pubitemid 27069203)
18. Själander A, Birgander R, Hallmans G, Cajander S, Lenner P, Athlin L, Beckman G, Beckman L,. p53 polymorphisms and haplotypes in breast cancer. Carcinogenesis 1996; 17: 1313-6.
19. Hong Y, Miao X, Zhang X, Ding F, Luo A, Guo Y, Tan W, Liu Z, Lin D,. The role of P53 and MDM2 polymorphisms in the risk of oesophageal squamous cell carcinoma. Cancer Res 2005; 65: 9582-7. (Pubitemid 41508029)
20. Yang W, Zhang Y, Tian X, Ning T, Ke Y,. p53 codon 72 polymorphism and the risk of oesophageal squamous cell carcinoma. Mol Carcinog 2008; 47: 100-4. (Pubitemid 351231438)
21. Shao Y, Tan W, Zhang S,. p53 gene codon 72 polymorphism and risk of oesophageal squamous cell carcinoma: a case-control study in a Chinese population. Dis Esophagus 2008; 2: 139-43. (Pubitemid 351247326)
22. Hu N, Li WJ, Su H, Wang C, Goldstein AM, Albert PS, Emmert-Buck MR, Kong LH, Roth MJ, Dawsey SM, He LJ, Cao SF, et al,. Common genetic variants of TP53 and BRCA2 in oesophageal cancer patients and healthy individuals from low and high risk areas of northern China. Cancer Detect Prev 2003; 27: 132-8. (Pubitemid 36429593)
23. Szymanowska A, Jassem E, Dziadziuszko R, Borg A, Limon J, Kobierska-Gulida G, Rzyman W, Jassem J,. Increased risk of non-small cell lung cancer and frequency of somatic TP53 gene mutations in Pro72 carriers of TP53 Arg72Pro polymorphism. Lung Cancer 2006; 52: 9-14. (Pubitemid 43340193)
24. Popanda O, Edler L, Waas P, Schattenberg T, Butkiewicz D, Muley T, Dienemann H, Risch A, Bartsch H, Schmezer P,. Elevated risk of squamous cell carcinoma of the lung in heavy smokers carrying the variant alleles of the TP53 Arg72Pro and p21 Ser31Arg polymorphisms. Lung Cancer 2007; 55: 25-34. (Pubitemid 46038874)
25. Nadji SA, Mahmoodi M, Ziaee AA, Naghshvar F, Torabizadeh J, Yahyapour Y, Nategh R, Mokhtari-Azad T,. An increased lung cancer risk associated with codon 72 polymorphism in the TP53 gene and human papillomavirus infection in Mazandaran province, Iran. Lung Cancer 2007; 56: 145-51. (Pubitemid 46590487)
26. Murata M, Tagawa M, Kimura M, Kimura H, Watanabe S, Saisho H,. Analysis of a germ line polymorphism of the p53 gene in lung cancer patients: discrete results with smoking history. Carcinogenesis 1996; 17: 261-4. (Pubitemid 26091303)
27. Dakouras A, Nikiteas N, Papadakis E, Perakis M, Valis D, Rallis G, Tzanakis N, Peros G, Tsigkris C, Kittas C, Karakitsos P,. P53Arg72 homozygosity and its increased incidence in left-sided sporadic colorectal adenocarcinomas in a Greek-Caucasian population. Anticancer Res 2008; 28: 1039-43. (Pubitemid 351578952)
28. Tan XL, Nikiteas N, Papadakis E, Perakis M, Valis D, Rallis G, Tzanakis N, Peros G, Tsigkris C, Kittas C, Karakitsos P,. Genetic polymorphisms in TP53, nonsteroidal anti-inflammatory drugs and the risk of colorectal cancer: evidence for gene-environment interaction? Pharmacogenet Genomics 2007; 17: 639-45.
29. Yan L, Zhang D, Chen C, Mao Y, Xie Y, Li Y, Huang Y, Han B,. TP53 Arg72Pro polymorphism and lung cancer risk: a meta-analysis. Int J Cancer 2009; 125: 2903-11.
30. Zhou Y, Li N, Zhuang W, Liu GJ, Wu TX, Yao X, Du L, Wei ML, Wu XT,. P53 codon 72 polymorphism and gastric cancer: a meta-analysis of the literature. Int J Cancer 2007; 121: 1481-6. (Pubitemid 47328706)
31. Klug SJ, Ressing M, Koenig J, Abba MC, Agorastos T, Brenna SM, Ciotti M, Das BR, Del Mistro A, Dybikowska A, Giuliano AR, Gudleviciene Z, et al,. TP53 codon 72 polymorphism and cervical cancer: a pooled analysis of individual data from 49 studies. Lancet Oncol 2009; 10: 772-84.
32. Borenstein M, Hedges LV, Higgins JPT, Rothstein HR,. Introduction to meta-analysis. UK: Wiley Publishing Group, 2009. 450.
33. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB,. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000; 283: 2008-12. (Pubitemid 30214957)
34. Minelli C, Thompson JR, Abrams KR, Thakkinstian A, Attia J,. The quality of meta-analyses of genetic association studies: a review with recommendations. Am J Epidemiol 2009; 170: 1333-43.
35. Francisco G, Menezes PR, Eluf-Neto J, Chammas, R., XPC polymorphisms play a role in tissue-specific carcinogenesis: a meta-analysis. Eur J Hum Genet 2008; 16: 724-34. (Pubitemid 351753369)
36. Higgins JP, Thompson SG, Deeks JJ, Altman DG,. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-60. (Pubitemid 37088507)
37. Egger M, Smith GD, Altaman DG,. Systematic Reviews in Health Care: Meta-analysis in Context. London: BMJ publishing group, 2001. 487.
38. Själander A, Birgander R, Saha N, Beckman L, Beckman G,. p53 polymorphisms and haplotypes show distinct differences between major ethnic groups. Hum Hered 1996; 46: 41-8. (Pubitemid 26002997)
39. Beckman G, Birgander R, Själander A, Saha N, Holmberg PA, Kivelä A, Beckman L,. Is p53 polymorphism maintained by natural selection? Hum Hered 1994; 44: 266-70. (Pubitemid 24229554)
40. Marin MC, Jost CA, Brooks LA, Irwin MS, O'Nions J, Tidy JA, James N, McGregor JM, Harwood CA, Yulug IG, Vousden KH, Allday MJ, et al,. A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat Genet 2000; 25: 47-54. (Pubitemid 30257035)
41. Tada M, Furuuchi K, Kaneda M, Matsumoto J, Takahashi M, Hirai A, Mitsumoto Y, Iggo RD, Moriuch, T,. Inactivate the remaining p53 allele or the alternate p73? Preferential selection of the Arg72 polymorphism in cancers with recessive p53 mutants but not transdominant mutants. Carcinogenesis 2001; 22: 515-7. (Pubitemid 32203833)
42. Bergamaschi D, Samuels Y, Sullivan A, Zvelebil M, Breyssens H, Bisso A, Del Sal G, Syed N, Smith P, Gasco M, Crook T, Lu X,. iASPP preferentially binds p53 proline-rich region and modulates apoptotic function of codon 72-polymorphic p53. Nat Genet 2006; 38: 1133-41. (Pubitemid 44470358)
43. Petitjean A, Achatz MI, Borresen-Dale AL, Hainaut P, Olivier M,. TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene 2007; 26: 2157-65. (Pubitemid 46536647)
44. Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P, Olivier M,. Impact of mutant p53 functional properties on TP53 mutation patterns and tumour phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 2007; 28: 622-9. (Pubitemid 46744292)
45. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM,. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990; 63: 1129-36. (Pubitemid 120035062)
46. Koushik A, Platt RW, Franco EL,. p53 codon 72 polymorphism and cervical neoplasia: a meta-analysis review. Cancer Epidemiol Biomarkers Prev 2004; 13: 11-22. (Pubitemid 38116615)
47. Haiman CA, Stram DO, Wilkens LR, Pike MC, Kolonel LN, Henderson BE, Le Marchand L,. Ethnic and racial differences in the smoking-related risk of lung cancer. N Engl J Med 2006; 354: 333-42. (Pubitemid 43145058)
48. Pietsch EC, Humbey O, Murphy ME,. Polymorphisms in the p53 pathway. Oncogene 2006; 25: 1602-11.
49. Ioannidis JP, Boffetta P, Little J, O'Brien TR, Uitterlinden AG, Vineis P, Balding DJ, Chokkalingam A, Dolan SM, Flanders WD, Higgins JP, McCarthy MI, et al,. Assessment of cumulative evidence on genetic associations: interim guidelines. Int J Epidemiol 2008; 37: 120-32. (Pubitemid 351228620)
50. Makni H, Franco EL, Kaiano J, Villa LL, Labrecque S, Dudley R, Storey A, Matlashewski G,. p53 polymorphism in codon 72 and risk of human papillomavirus-induced cervical cancer: effect of inter-laboratory variation. Int J Cancer 2000; 87: 528-33. (Pubitemid 30639812)